Longboard Pharmaceuticals, Inc.
NASDAQ:LBPH
29.31 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.005 | 0.005 | 0.001 | 0 |
| Gross Profit
| -0.005 | -0.005 | -0.001 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 43.752 | 34.638 | 19.774 | 4.633 |
| General & Administrative Expenses
| 13.007 | 10.16 | 8.065 | 9.767 |
| Selling & Marketing Expenses
| -0.005 | 0 | 0 | 0 |
| SG&A
| 13.002 | 10.16 | 8.065 | 9.767 |
| Other Expenses
| 0 | 0.016 | -0.022 | 0 |
| Operating Expenses
| 56.754 | 44.798 | 27.839 | 14.4 |
| Operating Income
| -56.759 | -44.798 | -27.839 | -14.4 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 2.337 | 0.853 | 0.042 | -0.007 |
| Income Before Tax
| -54.422 | -43.945 | -27.797 | -14.4 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0.853 | -0.064 | -0.014 |
| Net Income
| -54.422 | -43.092 | -27.733 | -14.4 |
| Net Income Ratio
| 0 | 0 | 0 | 0 |
| EPS
| -2.39 | -2.51 | -1.62 | -0.82 |
| EPS Diluted
| -2.39 | -2.51 | -1.62 | -0.82 |
| EBITDA
| -56.754 | -44.798 | -27.838 | -14.4 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 |